Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Shares Outstanding (Diluted Average) (2020 - 2025)

Oncology Institute (TOI) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $89.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 19.37% year-over-year to $89.3 million, compared with a TTM value of $89.3 million through Sep 2025, up 19.37%, and an annual FY2024 reading of $75.0 million, up 1.76% over the prior year.
  • Shares Outstanding (Diluted Average) was $89.3 million for Q3 2025 at Oncology Institute, down from $93.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $93.2 million in Q2 2025 and bottomed at $62.9 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $74.6 million, with a median of $74.2 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 1030.04% in 2021, then decreased 8.51% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $66.2 million in 2021, then grew by 21.7% to $80.6 million in 2022, then decreased by 8.51% to $73.7 million in 2023, then grew by 1.76% to $75.0 million in 2024, then increased by 19.04% to $89.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TOI at $89.3 million in Q3 2025, $93.2 million in Q2 2025, and $77.1 million in Q1 2025.